Francesca Vaglini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesca Vaglini has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Carla Pardini
Department of Translational Research and of New Surgical and Medical Technologies, via Roma 55, University of Pisa, 56126 Pisa, Italy
3 shared publicationsClaudio Gerace
Department of Translational Research New Technologies in Medicine and Surgery, University of Pisa, Italy
2 shared publicationsCristina Viaggi
Department of Translational Research New Technologies in Medicine and Surgery, University of Pisa, Italy
2 shared publicationsGiovanni U. Corsini
Department of Translational Research New Technologies in Medicine and Surgery, University of Pisa, Italy
2 shared publications- Marco Scarselli
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy
2 shared publications Alessandro Zuddas
Institute of Pharmacology, School of Medicine, University of Pisa, Italy
1 shared publication
Latest Publications
- 1 August 2019
- Published by Elsevier in Brain Research Bulletin
- Vol. 150, 290-296
Parkinson’s disease and light: The bright and the Dark sides
- 1 August 2019
- Published by Elsevier in Brain Research Bulletin
- Vol. 150, 290-296
Parkinson’s disease and light: The bright and the Dark sides
- 1 May 2019
- Published by Elsevier in NeuroToxicology
- Vol. 72, 51-60
Rho-inhibition and neuroprotective effect on rotenone-treated dopaminergic neurons in vitro
- 1 May 2019
- Published by Elsevier in NeuroToxicology
- Vol. 72, 51-60
Rho-inhibition and neuroprotective effect on rotenone-treated dopaminergic neurons in vitro
- 1 August 2015
- Published by Elsevier in Neurochemistry International
- Vol. 87, 34-42
Serotonin abnormalities in Engrailed-2 knockout mice: New insight relevant for a model of Autism Spectrum Disorder
- 1 August 2015
- Published by Elsevier in Neurochemistry International
- Vol. 87, 34-42
Serotonin abnormalities in Engrailed-2 knockout mice: New insight relevant for a model of Autism Spectrum Disorder
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 7, 50607
Acetaldehyde and parkinsonism: role of CYP450 2E1
The present review update the relationship between acetaldehyde and parkinsonism with a specific focus on the role of P450 system and CYP 2E1 isozyme particularly. We have indicated that acetaldehyde is able to enhance the parkinsonism induced in mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin able to damage the nigrostriatal dopaminergic pathway. Similarly diethyldithiocarbamate, the main metabolite of disulfiram, a drug widely used to control alcoholism, diallylsulfide and phenylisothiocyanate also markedly enhance the toxin-related parkinsonism. All these compounds are substrate/inhibitors of CYP450 2E1 isozyme. The presence of CYP 2E1 has been detected in the dopamine neurons of rodent Substantia Nigra, but a precise function of the enzyme has not been elucidated yet. By treating CYP 2E1 knockout mice with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, the Substantia Nigra induced lesion was significantly reduced when compared with the lesion observed in wild-type animals. Several in vivo and in vitro studies led to the conclusion that CYP 2E1 may enhance the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice by increasing free radical production inside the dopaminergic neurons. Acetaldehyde is a good substrate for CYP 2E1 enzyme as the other substrate-inhibitors and by this way may facilitate the susceptibility of dopaminergic neurons to toxic events. The literature suggests that ethanol and/or disulfiram may be responsible for toxic parkinsonism in human and it indicates that basal ganglia are the major targets of disulfiram toxicity. A very recent study reports that there are a decreased methylation of the CYP 2E1 gene and increased expression of CYP 2E1 mRNA in Parkinson’s Disease patient brains. This study suggests that epigenetic variants of this cytochrome contribute to the susceptibility, thus confirming multiples lines of evidence which indicate a link between environmental toxins and Parkinson’s Disease.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 7, 50607
Open AccessAcetaldehyde and parkinsonism: role of CYP450 2E1
The present review update the relationship between acetaldehyde and parkinsonism with a specific focus on the role of P450 system and CYP 2E1 isozyme particularly. We have indicated that acetaldehyde is able to enhance the parkinsonism induced in mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin able to damage the nigrostriatal dopaminergic pathway. Similarly diethyldithiocarbamate, the main metabolite of disulfiram, a drug widely used to control alcoholism, diallylsulfide and phenylisothiocyanate also markedly enhance the toxin-related parkinsonism. All these compounds are substrate/inhibitors of CYP450 2E1 isozyme. The presence of CYP 2E1 has been detected in the dopamine neurons of rodent Substantia Nigra, but a precise function of the enzyme has not been elucidated yet. By treating CYP 2E1 knockout mice with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, the Substantia Nigra induced lesion was significantly reduced when compared with the lesion observed in wild-type animals. Several in vivo and in vitro studies led to the conclusion that CYP 2E1 may enhance the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice by increasing free radical production inside the dopaminergic neurons. Acetaldehyde is a good substrate for CYP 2E1 enzyme as the other substrate-inhibitors and by this way may facilitate the susceptibility of dopaminergic neurons to toxic events. The literature suggests that ethanol and/or disulfiram may be responsible for toxic parkinsonism in human and it indicates that basal ganglia are the major targets of disulfiram toxicity. A very recent study reports that there are a decreased methylation of the CYP 2E1 gene and increased expression of CYP 2E1 mRNA in Parkinson’s Disease patient brains. This study suggests that epigenetic variants of this cytochrome contribute to the susceptibility, thus confirming multiples lines of evidence which indicate a link between environmental toxins and Parkinson’s Disease.
- 31 March 1992
- Published by Elsevier in Neurochemistry International
- Vol. 20, 287-293
Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehydehyde or diethyldithiocarbamate
- 31 March 1992
- Published by Elsevier in Neurochemistry International
- Vol. 20, 287-293
Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehydehyde or diethyldithiocarbamate